checkAd
    Ultragenyx Pharmaceutical Aktie
    42,20
     
    EUR
    +2,93 %
    +1,20 EUR
    Letzter Kurs 23.04.24 Tradegate
    42,20
     
    EUR
    143 STK
    Geldkurs 10:07:27
    42,40
     
    EUR
    142 STK
    Briefkurs 10:07:27
    ISIN: US90400D1081 · WKN: A1XCY0 · SYM: UP0 · USA

    Neueste Nachrichten

    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    19.04.24 · globenewswire · Ultragenyx Pharmaceutical
    Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
    15.04.24 · globenewswire · Ultragenyx Pharmaceutical
    Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
    12.04.24 · globenewswire · Ultragenyx Pharmaceutical
    Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
    12.04.24 · globenewswire · Ultragenyx Pharmaceutical
    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    22.03.24 · globenewswire · Ultragenyx Pharmaceutical
    Ultragenyx to Participate at Investor Conferences in March
    27.02.24 · globenewswire · Ultragenyx Pharmaceutical
    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    23.02.24 · globenewswire · Ultragenyx Pharmaceutical
    Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
    15.02.24 · globenewswire · Ultragenyx Pharmaceutical
    Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update
    08.02.24 · globenewswire · Ultragenyx Pharmaceutical
    Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)
    06.02.24 · globenewswire · Ultragenyx Pharmaceutical
    Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome
    05.02.24 · globenewswire · Ultragenyx Pharmaceutical
    Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
    25.01.24 · globenewswire · Ultragenyx Pharmaceutical